ergoline and Duodenal-Ulcer

ergoline has been researched along with Duodenal-Ulcer* in 2 studies

Other Studies

2 other study(ies) available for ergoline and Duodenal-Ulcer

Article	Year
Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1985, Volume: 180, Issue:3 Experiments in rats revealed that the parkinsonian drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) given in multiple daily doses either per os (p.o.) or subcutaneously (s.c.) induced in a dose-dependent manner solitary or double ("kissing") duodenal ulcers in the rat. MPTP also diminished cerebral concentrations of DOPAC and the duodenal ulcers were prevented by pretreatment with dopamine agonists (e.g., bromocriptine, lergotrile) or monoamine oxidase inhibitors (e.g., pargyline, 1-deprenyl). High doses of MPTP also caused gastric erosions and motility changes resembling parkinsonism (e.g., akinesia, rigidity, forward bending of trunk). This chemical decreased gastric secretion of acid and pepsin, as well as pancreatic bicarbonate, trypsin and amylase. Thus, MPTP causes duodenal ulcers that are possibly associated with impaired defense in the duodenal bulb (e.g., decreased availability of duodenal and pancreatic bicarbonate). Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amylases; Animals; Bicarbonates; Bromocriptine; Dose-Response Relationship, Drug; Duodenal Ulcer; Duodenum; Ergolines; Female; Gastric Acid; Gastric Emptying; Gastrointestinal Motility; Monoamine Oxidase Inhibitors; Pancreas; Pyridines; Rats; Rats, Inbred Strains; Trypsin	1985
Dopamine disorder in duodenal ulceration. Lancet (London, England), 1979, Oct-27, Volume: 2, Issue:8148 Cysteamine-induced duodenal ulcers in rats were prevented by the dopamine agonists bromocriptine, lergotrile, and apomorphine, whereas both the severity of duodenal ulcers and the mortality among cysteamine-treated rats were raised by the dopamine receptor antagonist, haloperiodol. Bromocriptine and lergotrile greatly reduced gastric-acid output in cysteamine-treated rats. A review of the literature shows a high incidence of duodenal ulcers in patients with Parkinson's disease (associated with dopamine deficiency) and a low occurrence in schizophrenics (associated with dopamine excess and/or hyperactivity). Thus, changes in peripheral and/or central dopamine concentrations and/or receptor activity may have a role in the pathogenesis of duodenal ulceration. Topics: Animals; Anti-Ulcer Agents; Apomorphine; Bromocriptine; Chemical Phenomena; Chemistry; Cysteamine; Dopamine; Drug Synergism; Duodenal Ulcer; Ergolines; Female; Gastric Juice; Haloperidol; Pimozide; Rats; Receptors, Dopamine	1979

Article

Year

Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).

Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1985, Volume: 180, Issue:3

Experiments in rats revealed that the parkinsonian drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) given in multiple daily doses either per os (p.o.) or subcutaneously (s.c.) induced in a dose-dependent manner solitary or double ("kissing") duodenal ulcers in the rat. MPTP also diminished cerebral concentrations of DOPAC and the duodenal ulcers were prevented by pretreatment with dopamine agonists (e.g., bromocriptine, lergotrile) or monoamine oxidase inhibitors (e.g., pargyline, 1-deprenyl). High doses of MPTP also caused gastric erosions and motility changes resembling parkinsonism (e.g., akinesia, rigidity, forward bending of trunk). This chemical decreased gastric secretion of acid and pepsin, as well as pancreatic bicarbonate, trypsin and amylase. Thus, MPTP causes duodenal ulcers that are possibly associated with impaired defense in the duodenal bulb (e.g., decreased availability of duodenal and pancreatic bicarbonate).

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amylases; Animals; Bicarbonates; Bromocriptine; Dose-Response Relationship, Drug; Duodenal Ulcer; Duodenum; Ergolines; Female; Gastric Acid; Gastric Emptying; Gastrointestinal Motility; Monoamine Oxidase Inhibitors; Pancreas; Pyridines; Rats; Rats, Inbred Strains; Trypsin

1985

Dopamine disorder in duodenal ulceration.

Lancet (London, England), 1979, Oct-27, Volume: 2, Issue:8148

Cysteamine-induced duodenal ulcers in rats were prevented by the dopamine agonists bromocriptine, lergotrile, and apomorphine, whereas both the severity of duodenal ulcers and the mortality among cysteamine-treated rats were raised by the dopamine receptor antagonist, haloperiodol. Bromocriptine and lergotrile greatly reduced gastric-acid output in cysteamine-treated rats. A review of the literature shows a high incidence of duodenal ulcers in patients with Parkinson's disease (associated with dopamine deficiency) and a low occurrence in schizophrenics (associated with dopamine excess and/or hyperactivity). Thus, changes in peripheral and/or central dopamine concentrations and/or receptor activity may have a role in the pathogenesis of duodenal ulceration.

Topics: Animals; Anti-Ulcer Agents; Apomorphine; Bromocriptine; Chemical Phenomena; Chemistry; Cysteamine; Dopamine; Drug Synergism; Duodenal Ulcer; Ergolines; Female; Gastric Juice; Haloperidol; Pimozide; Rats; Receptors, Dopamine

1979